|
1
|
Takagi Y, Hosomi Y, Oshita F, Okamoto H,
Seki N, Minato K, Aono H, Yamada K, Okuma Y, Hida N, et al:
Feasibility study of docetaxel plus bevacizumab as first line
therapy for elderly patients with advanced non-small-cell lung
cancer: Thoracic Oncology Research Group (TORG) 1014. BMC Cancer.
15:740–750. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kanda S, Horinouchi H, Fujiwara Y,
Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T and
Ohe Y: Cytotoxic chemotherapy may overcome the development of
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 89:287–293.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen J, Chen J, Ding HY, Pan QS, Hong WD,
Xu G, Yu FY and Wang YM: Use of an artificial neural network to
construct a model of predicting deep fungal infection in lung
cancer patients. Asian Pac J Cancer Prev. 16:5095–5099. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang BT, Lu JY, Lin PX, Chen JZ, Kuang Y
and Chen CZ: Comparison of two RapidArc delivery strategies in
stereotactic body radiotherapy of peripheral lung cancer with
flattening filter free beams. PLoS One. 10:e01275012015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kubota K, Sakai H, Katakami N, Nishio M,
Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K,
et al: Tokyo Cooperative Oncology Group: A randomized phase III
trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in
Japanese patients with advanced non-small-cell lung cancer:
TCOG0701 CATS trial. Ann Oncol. 26:1401–1408. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhuang X, Herbert JM, Lodhia P, Bradford
J, Turner AM, Newby PM, Thickett D, Naidu U, Blakey D, Barry S, et
al: Identification of novel vascular targets in lung cancer. Br J
Cancer. 112:485–494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morichika D, Sato-Hisamoto A, Hotta K,
Takata K, Iwaki N, Uchida K, Minami D, Kubo T, Tanimoto M and Kiura
K: Fatal Candida septic shock during systemic chemotherapy in lung
cancer patient receiving corticosteroid replacement therapy for
hypopituitarism: A case report. Jpn J Clin Oncol. 44:501–505. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Saito M, Saito W, Kanda A, Ohguro H and
Ishida S: A case of paraneoplastic optic neuropathy and outer
retinitis positive for autoantibodies against collapsin response
mediator protein-5, recoverin, and α-enolase. BMC Ophthalmol.
14:5–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gómez MT, Jiménez MF, Aranda JL, Rodríguez
M, Novoa NM and Varela G: The risk of bilobectomy compared with
lobectomy: A retrospective analysis of a series of matched cases
and controls. Eur J Cardiothorac Surg. 46:72–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Andreas S, Rittmeyer A, Hinterthaner M and
Huber RM: Smoking cessation in lung cancer-achievable and
effective. Dtsch Arztebl Int. 110:719–724. 2013.PubMed/NCBI
|
|
11
|
Fernández Lorente A, Brooks Acosta S,
Vinageras Neninger E, Alvarez Barroso MC, Brito Wilkinson B, Troche
Concepción M, Martínez Pérez LB, González Viada CE, Diaz Crespo T
and Casacó Parada AR: Effect of blockade of the EGF system on wound
healing in patients vaccinated with CIMAvax® EGF. World
J Surg Oncol. 11:2752013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goss GD, O'Callaghan C, Lorimer I, Tsao
MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F,
et al: Gefitinib versus placebo in completely resected
non-small-cell lung cancer: Results of the NCIC CTG BR19 study. J
Clin Oncol. 31:3320–3326. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang YH, Terabe M, Pendleton CD,
Khursigara Stewart D, Bera TK, Pastan I and Berzofsky JA:
Identification and enhancement of HLA-A2.1-restricted CTL epitopes
in a new human cancerantigen-POTE. PLoS One. 8:643–665. 2013.
|
|
14
|
Ai Yang SS, Hsu K, Herbert C, Cheng Z,
Hunt J, Lewis CR and Thomas PS: Mitochondrial DNA mutations in
exhaled breath condensate of patients with lung cancer. Respir Med.
107:911–918. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Noro R, Yoshimura A, Yamamoto K, Miyanaga
A, Mizutani H, Minegishi Y, Seike M, Kubota K, Kosaihira S, Hino M,
et al: East Japan Chesters Group: Alternating chemotherapy with
amrubicin plus cisplatin and weekly administration of irinotecan
plus cisplatin for extensive-stage small cell lung cancer.
Anticancer Res. 33:1117–1123. 2013.PubMed/NCBI
|
|
16
|
Kikuchi R, Isowa N, Tokuyasu H, Kawasaki
Y, Onuma H, Miura H, Terada M, Takada T, Gejyo F, Suzuki E, et al:
Three cases of resected pleomorphic carcinoma. Ann Thorac
Cardiovasc Surg. 16:264–269. 2010.PubMed/NCBI
|
|
17
|
Tanaka J, Tajima S, Ito R, Shimaoka Y,
Kuriyama H, Kagamu H, Terada M, Takada T, Gejyo F, Suzuki E, et al:
Non-small cell lung carcinoma dying of acute respiratory failure
due to aerogenous metastasis. Nihon Kokyuki Gakkai Zasshi.
47:652–657. 2009.(In Japanese). PubMed/NCBI
|
|
18
|
Van Arsdale SA: Chest mass mimicking an
implanted port. Clin J Oncol Nurs. 12:673–674. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wampler GL, Ahlgren JD, Lokich JJ, Gullo
JJ and Phillips JA: Dichloromethotrexate, infusional cisplatin, and
infusional 5-fluorouracil for locally advanced or metastatic
non-small cell lung cancer. A MAOP study. Am J Clin Oncol.
14:442–445. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Belch AR, Urtasun RC, Bodnar D, Kinney B
and Amy R: Use of hemibody irradiation as a non-cross-resistant
agent in combination with systematic chemotherapy in small cell
lung cancer. NCI Monogr. 11:271–274. 1988.
|
|
21
|
Evans WK, Feld R, Murray N, Pater J,
Shelley W, Willan A, Osoba D, Levitt M, Coy P, Hodson I, et al: The
use of VP-16 plus cisplatin during induction chemotherapy for
small-cell lung cancer. Semin Oncol. 13 Suppl 3:10–16.
1986.PubMed/NCBI
|
